Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
NurExone Biologic Inc. (NRXBF) had Stock-Based Compensation of $0.64M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-1.85M |
|
-- |
|
-- |
|
$1.82M |
|
$-1.82M |
|
$-0.02M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.82M |
|
$-1.78M |
|
76.03M |
|
76.03M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$1.95M |
|
$0.78M |
|
$0.91M |
|
$2.86M |
|
$1.01M |
|
-- |
|
$0.33M |
|
$1.33M |
|
$1.53M |
|
$1.53M |
|
$1.53M |
|
80.01M |
|
| Cash Flow Statement Financials | |
$-2.05M |
|
$-0.03M |
|
$2.50M |
|
$0.70M |
|
$1.23M |
|
$0.53M |
|
|
Stock-Based Compensation |
$0.64M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.94 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.09M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-120.50% |
|
-120.50% |
|
-64.46% |
|
-120.50% |
|
$0.02 |
|
$-0.03 |
|
$-0.03 |
|